马来酸罗格列酮 T1622

Product Introduction
Bioactivity


英文名: Rosiglitazone maleate

描述: Rosiglitazone maleate (BRL 49653) 是一种选择性PPARγ激活剂，具有抗糖尿病特性和潜在抗肿瘤活性。它也是TRP 通道调节剂，可抑制 TRPM2、TRPM3 的活性，激活 TRPC5。

体内活性: 在许多细胞系中,Rosiglitazone能够抑制胆固醇合成。在AMPKα亚基内,Rosiglitazone激活含有α1和α2的AMPK复合物,能够增加磷酸化。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 87 mg/mL (183.9 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)


关键字: TRP Channel | Ferroptosis | BRL-49653 | Autophagy | inhibit | Rosiglitazone maleate | Transient receptor potential channels | Rosiglitazone Maleate | Peroxisome proliferator-activated receptors | BRL49653 | PPAR | Inhibitor | Rosiglitazone

相关产品: Artesunate | Ammonium iron(III) citrate | FA16 | (-)-Epicatechin | Eprenetapopt | Anticancer agent 147 | FIN56 | Setanaxib | GPX4-IN-7 | U-73122

相关库: FDA-Approved Drug Library | Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library | EMA Approved Drug Library | NO PAINS Compound Library

马来酸罗格列酮 T1622信息由TargetMol中国为您提供，如您想了解更多关于马来酸罗格列酮 T1622报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途